Market Cap 530.17M
Revenue (ttm) 10.00M
Net Income (ttm) -29.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 28,075
Avg Vol 812,584
Day's Range N/A - N/A
Shares Out 140.26M
Stochastic %K 30%
Beta 0.88
Analysts Strong Sell
Price Target $6.80

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 33 3023 7300
Address:
One Cavendish Place, 4th Floor, London, United Kingdom
Mjcwo
Mjcwo Oct. 3 at 5:17 PM
$MREO ready for the launch….
0 · Reply
ClenchFists
ClenchFists Oct. 3 at 2:23 PM
$MREO Ready!!
0 · Reply
Abduld3
Abduld3 Oct. 2 at 10:21 PM
1 · Reply
sohaylem
sohaylem Oct. 2 at 7:32 PM
$MREO does anyone know why the volume is so high?
1 · Reply
Newcar
Newcar Oct. 2 at 4:40 PM
$MREO fake dump before BOOOMMM
0 · Reply
lidopete
lidopete Oct. 2 at 12:32 PM
$MREO $RARE Ultragenyx placed on 'Positive Catalyst Watch' at JPMorgan JPMorgan analyst Anupam Rama placed shares of Ultragenyx on "Positive Catalyst Watch" ahead of the company's ORBIT and COSMIC study updates. The firm has confidence in setrusumab's clinical success and keeps an Overweight rating on the shares with a $125 price target. At current share levels, JPMorgan sees a "very positive" reward/risk profile heading into the updates with more win scenarios than downside scenarios. Note, MREO is RARE's partner with setrusumab
1 · Reply
TragicRain
TragicRain Oct. 1 at 6:13 PM
$MREO - So far - you said No GOV shutdown..I said yes..... (2) - We just closed a gap set back in 8/12....and we have a little bounce...it either goes up or heads down to the next gap...which is the 4.30(ish) range...
1 · Reply
Mjcwo
Mjcwo Oct. 1 at 5:22 PM
$MREO super bullish here
0 · Reply
Young_Antarian
Young_Antarian Oct. 1 at 5:02 PM
$MREO ready to gap > $2.05 —> $2.90
0 · Reply
Hoekie12
Hoekie12 Oct. 1 at 5:27 AM
$MREO Rubric Capital is an hedgefund which invests heavy in biotech company’s. They are pushing sometimes companies to a buyout for making a large profit and development of the medicines/therapies. Guess what, they are 10% plus investing in MREO 😉
2 · Reply
Latest News on MREO
Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 12, 2025, 11:05 AM EST - 9 months ago

Mereo BioPharma Provides Update on Lead Clinical Programs


Mereo BioPharma Sends Letter to Rubric Capital Management

Aug 31, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Sends Letter to Rubric Capital Management


Why Mereo BioPharma Shares Are Jumping Today

Jun 17, 2022, 10:39 AM EDT - 3 years ago

Why Mereo BioPharma Shares Are Jumping Today


AstraZeneca weighing bid for Mereo BioPharma: report

Jun 17, 2022, 3:44 AM EDT - 3 years ago

AstraZeneca weighing bid for Mereo BioPharma: report

AZN


Mjcwo
Mjcwo Oct. 3 at 5:17 PM
$MREO ready for the launch….
0 · Reply
ClenchFists
ClenchFists Oct. 3 at 2:23 PM
$MREO Ready!!
0 · Reply
Abduld3
Abduld3 Oct. 2 at 10:21 PM
1 · Reply
sohaylem
sohaylem Oct. 2 at 7:32 PM
$MREO does anyone know why the volume is so high?
1 · Reply
Newcar
Newcar Oct. 2 at 4:40 PM
$MREO fake dump before BOOOMMM
0 · Reply
lidopete
lidopete Oct. 2 at 12:32 PM
$MREO $RARE Ultragenyx placed on 'Positive Catalyst Watch' at JPMorgan JPMorgan analyst Anupam Rama placed shares of Ultragenyx on "Positive Catalyst Watch" ahead of the company's ORBIT and COSMIC study updates. The firm has confidence in setrusumab's clinical success and keeps an Overweight rating on the shares with a $125 price target. At current share levels, JPMorgan sees a "very positive" reward/risk profile heading into the updates with more win scenarios than downside scenarios. Note, MREO is RARE's partner with setrusumab
1 · Reply
TragicRain
TragicRain Oct. 1 at 6:13 PM
$MREO - So far - you said No GOV shutdown..I said yes..... (2) - We just closed a gap set back in 8/12....and we have a little bounce...it either goes up or heads down to the next gap...which is the 4.30(ish) range...
1 · Reply
Mjcwo
Mjcwo Oct. 1 at 5:22 PM
$MREO super bullish here
0 · Reply
Young_Antarian
Young_Antarian Oct. 1 at 5:02 PM
$MREO ready to gap > $2.05 —> $2.90
0 · Reply
Hoekie12
Hoekie12 Oct. 1 at 5:27 AM
$MREO Rubric Capital is an hedgefund which invests heavy in biotech company’s. They are pushing sometimes companies to a buyout for making a large profit and development of the medicines/therapies. Guess what, they are 10% plus investing in MREO 😉
2 · Reply
kcarroll92
kcarroll92 Oct. 1 at 12:07 AM
$MREO comin in hot
0 · Reply
Abduld3
Abduld3 Sep. 30 at 10:07 PM
$MREO Ill take it
0 · Reply
cheetohottaki
cheetohottaki Sep. 30 at 8:47 PM
$MREO look at all the noobs who think they know what this is gonna do…..comical
0 · Reply
PDM5
PDM5 Sep. 30 at 5:18 PM
$MREO Run into data officially underway
1 · Reply
Cullousus
Cullousus Sep. 30 at 4:02 PM
$MREO the accumulation zone is drying up. Soon to be in demand.
0 · Reply
highnihilism
highnihilism Sep. 30 at 9:56 AM
$URGN Urogen Pharma: 80 trades, $142K vs $654K avg (0.22x !!!!). $44K calls / $98K puts. $WRBY Warby Parker: 76 trades, $68K vs $171K avg (0.40x !!). $44K calls / $24K puts. $MREO Mereo Biopharma: 35 trades, $44K vs $43K avg (1.02x). $44K calls / $0.06K puts. $NBIX Neurocrine: 14 trades, $46K vs $141K avg (0.32x !!). $44K calls / $2K puts.
0 · Reply
Abduld3
Abduld3 Sep. 30 at 8:05 AM
$MREO Close above $2.05 today too much to ask for?
1 · Reply
LoneBroker
LoneBroker Sep. 30 at 7:03 AM
$MREO$1.96 🐂 • RSI 60.3 • ATR 0.09% • vol↑ Support & Resistance — UPDATED 09/29/2025 3 Days | Support: $1.92 – $1.99 | Resistance: $1.99 7 Days | Support: $1.74 – $1.99 | Resistance: $1.99 MREO is trading at $1.96 as of 09/29/2025. RSI indicates 🐂 momentum, while ATR reflects modest daily volatility. Volume is vol↑, and the stock is testing short-term and weekly levels that could define direction. 🌐 Recent activity around lower-priced biotech equities highlights investor focus on funding prospects and regulatory updates. Market participants are also reacting to broader small-cap sentiment shifts, where liquidity swings have been amplifying short-term volatility. This backdrop suggests MREO may remain headline-sensitive in the near term. 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 😐 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 4:00 PM ET / 1:00 PM PT (Mon–Fri)
0 · Reply
Abduld3
Abduld3 Sep. 29 at 10:40 PM
$MREO End the month with a bang big bro
0 · Reply
Mjcwo
Mjcwo Sep. 29 at 3:32 PM
$MREO going to $5 near term…
0 · Reply
poot_buttagina
poot_buttagina Sep. 29 at 2:13 PM
$MREO Lot of early volume but staying compressed. Let's see which way it goes when vol slows. Usually down is the way, but if it breaks 2.00 before falling then all bets are off as the gap after 2.05 will begin to be filled.
0 · Reply
poot_buttagina
poot_buttagina Sep. 29 at 1:20 PM
$MREO So it looks like we should test 1.80 today or tomorrow before finishing aroun 2.00 by end of week. GL
0 · Reply